Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Clinical research associate

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44334   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    64 result(s) found for: Clinical research associate. Displaying page 1 of 4.
    1  2  3  4  Next»
    EudraCT Number: 2011-006209-83 Sponsor Protocol Number: 2011/198/HP Start Date*: Information not available in EudraCT
    Sponsor Name:CHU - Hôpitaux de Rouen
    Full Title: Evaluation of the Immune Response against Neisseria meningitidis B:14, P1-7,16 in subjects inoculated by MenBVac ® vaccine.
    Medical condition: Immunogenic Study, in french children living in the region of Normandy, France, after vaccination for B:14:P1.7,16, to evaluate the longer-term persistence of antibodies against B:14P1.7,16. bacter...
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029205 - Nervous system disorders 10027203 Meningeal bacterial infections HLT
    Population Age: Children, Under 18 Gender: Male, Female
    Trial protocol: FR (Completed)
    Trial results: (No results available)
    EudraCT Number: 2011-006268-27 Sponsor Protocol Number: 2011/199/HP Start Date*: Information not available in EudraCT
    Sponsor Name:CHU - Hôpitaux de Rouen
    Full Title: Evaluation of the Immune Response against Neisseria meningitidis B:14,P1-7,16 in subjects inoculated by MenBVac (R) vaccine.
    Medical condition: Immunogenic Study, in french children living in the region of Normandy, France, after vaccination for B:14,P1-7,16 bacterial strain.
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029205 - Nervous system disorders 10027203 Meningeal bacterial infections HLT
    Population Age: Children, Under 18 Gender: Male, Female
    Trial protocol: FR (Completed)
    Trial results: (No results available)
    EudraCT Number: 2015-004875-61 Sponsor Protocol Number: 15778303 Start Date*: 2016-02-05
    Sponsor Name:CHU TOULOUSE
    Full Title: Influence of apelin on insulin sensitivity in type 2 diabetic volunteers
    Medical condition: type 2 diabetes
    Disease:
    Population Age: Adults Gender: Male
    Trial protocol: FR (Completed)
    Trial results: (No results available)
    EudraCT Number: 2009-011044-20 Sponsor Protocol Number: D1710C00006 Start Date*: 2009-04-08
    Sponsor Name:AstraZeneca AB
    Full Title: A Single-Centre, Double-blind, Double-dummy, Randomised, Placebo Controlled, Four Period Crossover Study to Assess the Effect of Single Oral Doses of AZD5672 (600mg and 150mg) on QT/QTc Interval, C...
    Medical condition: rheumatoid arthritis
    Disease: Version SOC Term Classification Code Term Level
    9.1 10039075 Rheumatoid arthritis and associated conditions HLT
    Population Age: Adults Gender: Male
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2013-002094-22 Sponsor Protocol Number: 2013MM002B Start Date*: 2013-08-29
    Sponsor Name:Royal Brompton and Harefield NHS Foundation Trust (RB&HFT)
    Full Title: Comparison of ultra-low-dose Oral versus Transdermal Hormone Therapy on coagulation activation and metabolic risk factors for Cardiovascular Disease
    Medical condition: The effect of oestrogen replacement therapy taken either orally or transdermally and observing any likely benefit of both these therapies on the risks Venous thromobembolic events and cardiovascul...
    Disease: Version SOC Term Classification Code Term Level
    16.1 10038604 - Reproductive system and breast disorders 10027309 Menopause and related conditions HLGT
    Population Age: Adults Gender: Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2017-003159-44 Sponsor Protocol Number: SOGUG-2017-A-IEC(VEJ)-1 Start Date*: 2018-09-27
    Sponsor Name:Spanish Oncology Genitourinary Group
    Full Title: Phase II trial of durvalumab (Medi4736) plus tremelimumab with concurrent radiotherapy in patients with localized muscle invasive bladder cancer treated with a selective bladder preservation approach
    Medical condition: Localized muscle invasive bladder cancer
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10022878 Invasive bladder cancer stage II LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: View results
    EudraCT Number: 2020-003008-15 Sponsor Protocol Number: CAPRI2 Start Date*: 2021-05-27
    Sponsor Name:GRUPPO ONCOLOGICO DELL'ITALIA MERIDIONALE
    Full Title: CAPRI 2 GOIM study: investigate the efficacy and safety of a biomarker-driven cetuximab-based treatment regimen over 3 treatment lines in mCRC patients with RAS/BRAF wt tumors at start of first line.
    Medical condition: mCRC patients with RAS/BRAF wild type tumors at start of first line treatment
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004864 10052362 Metastatic colorectal cancer LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2009-012666-31 Sponsor Protocol Number: OG09/8956 Start Date*: 2009-11-11
    Sponsor Name:Leeds Teaching Hospitals and University of Leeds
    Full Title: The role of progesterone support and genetic polymorphisms for inflammatory cytokines on the risk of developing ovarian hyperstimulation syndrome (OHSS) in women undergoing In-Vitro fertilisation/I...
    Medical condition: Ovarian Hyperstimulation syndrome
    Disease: Version SOC Term Classification Code Term Level
    14.0 10038604 - Reproductive system and breast disorders 10033266 Ovarian hyperstimulation syndrome PT
    Population Age: Adults Gender: Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2010-022509-17 Sponsor Protocol Number: ML25434 Start Date*: 2010-12-13
    Sponsor Name:Roche Farmacêutica Química, Lda
    Full Title: Phase II, open-label study of erlotinib (Tarceva®) treatment in patients with locally advanced or metastatic non-small cell lung cancer who present activating mutations in the tyrosine kinase domai...
    Medical condition: Patients with histologically or cytologically confirmed locally advanced or metastatic NSCLC who have not received previous chemotherapy for their disease and who present activating mutations in th...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: PT (Completed)
    Trial results: View results
    EudraCT Number: 2018-000777-80 Sponsor Protocol Number: SENS111-202 Start Date*: 2018-06-08
    Sponsor Name:Sensorion
    Full Title: A randomized, cross-over, placebo controlled, and meclizine calibrated study to assess the safety and pharmacodynamic effects of SENS-111 (100 mg and 200 mg) single dose in healthy subjects exposed...
    Medical condition: healthy volunteers (medicine for acute unilateral vertigo)
    Disease:
    Population Age: Adults Gender: Male
    Trial protocol: NL (Completed)
    Trial results: View results
    EudraCT Number: 2021-005723-20 Sponsor Protocol Number: RC31/20/0445 Start Date*: 2022-02-10
    Sponsor Name:CHU de Toulouse
    Full Title: Evaluation of Botulinum TOXin type A in the treatment of Buerger’s disease
    Medical condition: This study assesses the feasibility and safety of treatment with botulinum toxin injection in patients with Buerger's disease
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2015-001721-16 Sponsor Protocol Number: 2014_09 Start Date*: 2015-07-24
    Sponsor Name:Centre Hospitalier Régional et Universitaire de Lille
    Full Title: SUFENTANIL maternal and foetal pharmacokinetic evaluation after intra–amniotic injection
    Medical condition:
    Disease: Version SOC Term Classification Code Term Level
    18.0 10022891 - Investigations 10053098 Foetal and neonatal investigations HLGT
    Population Age: In utero, Under 18, Adults Gender: Female
    Trial protocol: FR (Completed)
    Trial results: (No results available)
    EudraCT Number: 2006-000468-95 Sponsor Protocol Number: AZ3106242 Start Date*: 2006-06-16
    Sponsor Name:GlaxoSmithKline Research & Development Ltd
    Full Title: A double-blind, randomised, placebo-controlled, parallel group study to investigate the effects of SB-742457, donepezil and placebo on cognition in subjects with mild to moderate Alzheimer's Disease
    Medical condition: Alzheimer's disease
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) GB (Completed) AT (Completed) SK (Completed) EE (Completed) HU (Completed)
    Trial results: View results
    EudraCT Number: 2012-003330-16 Sponsor Protocol Number: GBG74 Start Date*: 2013-02-26
    Sponsor Name:GBG Forschungs GmbH (German Breast Group)
    Full Title: Randomized, open-label, phase II study comparing the efficacy and the safety of cabazitaxel versus weekly paclitaxel given as neo-adjuvant treatment in patients with operable Triple Negative or lum...
    Medical condition: Breast Cancer in patients with operable Triple Negative or luminal B/HER2 normal patients
    Disease: Version SOC Term Classification Code Term Level
    17.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10006187 Breast cancer PT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2012-000058-73 Sponsor Protocol Number: LIPS Start Date*: 2012-09-14
    Sponsor Name:University of Liverpool [...]
    1. University of Liverpool
    2. Walton Centre NHS Foundation Trust
    Full Title: A multi-centre (UK) double-blind randomised parallel group placebo controlled trial to evaluate the efficacy, safety, and tolerability of Intravenous Immunoglobulin (IVIg) 0.5g/kg plus standard tre...
    Medical condition: Complex Regional Pain Syndrome
    Disease: Version SOC Term Classification Code Term Level
    14.1 100000004867 10049475 Chronic pain LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2015-001361-27 Sponsor Protocol Number: ICR-CTSU/2015/10054 Start Date*: 2016-09-21
    Sponsor Name:The Institute of Cancer Research
    Full Title: CTC-STOP: Utilising Circulating Tumour Cell (CTC) Counts to Optimize Systemic Therapy of Metastatic Prostate Cancer.
    Medical condition: Advanced Castration Resistant Prostate Cancer
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004864 10001198 Adenocarcinoma of the prostate metastatic LLT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: GB (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2014-000540-15 Sponsor Protocol Number: SPON1266-14 Start Date*: 2014-05-01
    Sponsor Name:Cardiff University
    Full Title: Prostaglandin F2-alpha eye drops (Bimatoprost) in thyroid eye disease: a randomised controlled double blind crossover trial
    Medical condition: Graves' ophthalmopathy
    Disease: Version SOC Term Classification Code Term Level
    16.1 100000004853 10057889 Graves' ophthalmopathy LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2015-001048-12 Sponsor Protocol Number: GEIS40 Start Date*: 2015-10-13
    Sponsor Name:GEIS (Grupo Español de Investigación en Sarcomas)
    Full Title: Phase II, single arm, non-randomized and multicenter clinical trial of regorafenib as a single agent in the first-line setting for patients with metastatic and/or unresectable KIT/PDGFR Wild Type GIST
    Medical condition: KIT/PDGFR wild type GastroIntestinal Stromal Tumor (GIST)
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: ES (Ongoing) IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2017-000947-41 Sponsor Protocol Number: RC-P0055 Start Date*: 2017-08-18
    Sponsor Name:Groupement des Hôpitaux de l’Institut Catholique de Lille
    Full Title: ABATACEPT VERSUS TOCILIZUMAB BY SUBCUTANEOUS ADMINISTRATION FOR THE TREATMENT OF RHEUMATOID ARTHRITIS IN TNF ALPHA INHIBITOR INADEQUATE RESPONDER PATIENTS: A RANDOMIZED, OPEN-LABELED, SUPERIORITY T...
    Medical condition: Adults patients suffering from rheumatoid arthritis and in adequate response to a first line of treatment with a TNF alpha inhibitor.
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004870 10039075 Rheumatoid arthritis and associated conditions HLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2012-002029-31 Sponsor Protocol Number: CRUKD/12/002 Start Date*: 2013-11-19
    Sponsor Name:Cancer Research UK
    Full Title: A Cancer Research UK Phase I/II study to compare [124I]mIBG PET/CT to [123I]mIBG imaging in patients with metastatic neuroblastoma
    Medical condition: newly diagnosed, relapsed or refractory metastatic neuroblastoma
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10029260 Neuroblastoma PT
    Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  4  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sun May 04 12:35:26 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA